• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Unicycive Therapeutics Inc.

    5/8/24 4:05:39 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UNCY alert in real time by email
    DEFA14A 1 ea0205541-defa14a_unicycive.htm DEFINITIVE ADDITIONAL MATERIALS

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A 

     

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant

     

    Check the appropriate box: 

     

    ☐Preliminary Proxy Statement
      
    ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
      
    ☐Definitive Proxy Statement
      
    ☒Definitive Additional Materials
      
    ☐Soliciting Material under §240.14a-12

     

    Unicycive Therapeutics, Inc.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒ No fee required

     

    ☐ Fee paid previously with preliminary materials.

     

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11

     

    Payment of Filing Fee (Check the appropriate box):

     

     

     

    1

     

     

    Unicycive Therapeuctics, Inc.

    Amendment and Supplement to the Proxy Statement

    For the Annual Meeting of Stockholders

    To be Held on June 20, 2024

     

    EXPLANATORY NOTE

     

    On April 26, 2024, Unicycive Therapeuctics, Inc. (“Unicycive” or the “Company”) filed its definitive proxy statement (the “Proxy Statement”) with the Securities and Exchange Commission (“SEC”) for its annual meeting of shareholders to be held on June 20, 2024 (the “Annual Meeting”).

     

    The Company has retained Alliance Advisors as its strategic shareholder advisor and proxy solicitation agent in connection with the solicitation of proxies for the Annual Meeting.

     

    The Company is voluntarily amending and supplementing the Proxy Statement with the information provided in this amendment and supplement to the Proxy Statement (the “Amendment and Supplement”) to disclose the retainment of strategic shareholder advisor and proxy solicitation agent. This Amendment and Supplement is being filed with the SEC on or about May 8, 2024.

     

    Any proxies submitted by stockholders before the date of this Amendment and Supplement will be voted as instructed on those proxies, unless a stockholder changes his or her vote by submitting a later dated proxy. Stockholders should follow the instructions described in the Proxy Statement regarding how to submit proxies or vote at the Annual Meeting.

     

    THIS AMENDMENT AND SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT.

     

    This supplemental information should be read in conjunction with the Proxy Statement, which should be read in its entirety. Section references in the below disclosures are to sections in the Proxy Statement, and defined terms used but not defined herein have the meanings set forth in the Proxy Statement. To the extent the following information differs from or conflicts with the information contained in the Proxy Statement, the information set forth below shall be deemed to supersede the respective information in the Proxy Statement.

      

    Amendments and Supplemental Disclosure

     

    Notice

     

    Immediately above “By the Order of the Board of Directors” in the Notice, the following will be inserted:

     

    “If you have any questions or need assistance voting your shares, please call Alliance Advisors at:

     

     

     

     

     

    Strategic Shareholder Advisor and Proxy Solicitation Agent

    200 Broadacres Drive

    Bloomfield, NJ 07003

    North American Toll Free Phone:

    1-833-501-4837

    Email: [email protected]

    Call Collect Outside North America: 1-209-692-6143”

     

    2

     

     

    Proxy Statement

     

    The text under the heading “QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING— Who is Paying for the Expenses Involved in Preparing and Mailing this Proxy Statement?” is amended and restated as follows (new text in bold and underline):

     

    “All of the expenses involved in preparing, assembling and mailing these proxy materials and all costs of soliciting proxies will be paid by us. In addition to the solicitation by mail, proxies may be solicited by our officers and other employees by telephone or in person. Such persons will receive no compensation for their services other than their regular salaries. Arrangements will also be made with brokerage houses and other custodians, nominees and fiduciaries to forward solicitation materials to the beneficial owners of the shares held of record by such persons, and we may reimburse such persons for reasonable out of pocket expenses incurred by them in forwarding solicitation materials. In addition, we have retained Alliance Advisors as our strategic shareholder advisor and proxy solicitation agent in connection with the solicitation of proxies for the Annual Meeting at an approximate cost of $12,500, plus $5,000 for expenses. If you have any questions or require any assistance with completing your proxy, please contact Alliance Advisors by telephone (toll-free within North America) at 1-833-501-4837 or (call collect outside North America) at 1-209-692-6143 or by email at [email protected].

     

    3

     

     

    Get the next $UNCY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UNCY

    DatePrice TargetRatingAnalyst
    4/21/2025$6.00Buy
    Guggenheim
    4/4/2024$9.00Overweight
    Piper Sandler
    8/9/2021$13.50Buy
    Roth Capital
    More analyst ratings

    $UNCY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit

    LOS ALTOS, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026, at 1:30 p.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. To schedule a 1x1 meeting with management, please contact your Guggenheim conference representative. About Unicycive Therapeutics Uni

    2/4/26 7:05:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

    FDA assigns Prescription Drug User Fee Act (PDUFA) target date of June 29, 2026Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company's investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Th

    1/29/26 9:15:49 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

    DA assigns Prescription Drug User Fee Act (PDUFA) target date of June 27, 2026Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company's investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The

    1/29/26 7:05:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UNCY
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Unicycive Therapeutics Inc.

    SCHEDULE 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    2/10/26 1:15:05 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Unicycive Therapeutics Inc.

    SCHEDULE 13G - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    1/23/26 4:41:09 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Unicycive Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)

    11/14/25 5:10:14 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UNCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Aggarwal Gaurav converted options into 652,900 shares (SEC Form 4)

    4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)

    8/26/25 5:06:30 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kenkare-Mitra Sara

    4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)

    7/30/25 4:30:14 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP of Corporate Strategy Jermasek Douglas

    4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)

    7/30/25 4:30:06 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UNCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Unicycive Therapeutics with a new price target

    Guggenheim initiated coverage of Unicycive Therapeutics with a rating of Buy and set a new price target of $6.00

    4/21/25 8:39:22 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Unicycive Therapeutics with a new price target

    Piper Sandler initiated coverage of Unicycive Therapeutics with a rating of Overweight and set a new price target of $9.00

    4/4/24 8:18:34 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Unicycive Therapeutics with a new price target

    Roth Capital initiated coverage of Unicycive Therapeutics with a rating of Buy and set a new price target of $13.50

    8/9/21 9:57:19 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UNCY
    Financials

    Live finance-specific insights

    View All

    Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

    -   Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end -   Presented new analysis of OLC data at American Society of Nephrology (ASN) which demonstrates that OLC significantly reduced pill burden in terms of both pill volume (7x) and pill count (2x) compared to currently available phosphate binders -   Ended Q3 with $42.7 million of cash with expected runway into 2027 LOS ALTOS, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for t

    11/12/25 7:05:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

    - Type A Meeting requested with U.S. Food and Drug Administration (FDA) for resolution of the Complete Response Letter (CRL) for oxylanthanum carbonate (OLC) - OLC pivotal study data, published in the Clinical Journal of the American Society of Nephrology (CJASN), demonstrated OLC was well tolerated and enabled serum phosphate control in over 90% of patients with a low pill burden - Ended Q2 with $22.3 million of cash with expected runway into the second half of 2026 LOS ALTOS, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney dise

    8/14/25 7:00:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

    - Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated commercial launch in late 2025 - New data from patient surveys and patient-reported outcomes studies highlight adherence challenges for patients with hyperphosphatemia on dialysis and emphasize the market potential of OLC LOS ALTOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial

    5/14/25 7:15:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UNCY
    Leadership Updates

    Live Leadership Updates

    View All

    Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD

    LOS ALTOS, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced the appointment of Sara Kenkare-Mitra, PhD to the Company's Board of Directors, effective September 6, 2023. As a veteran of the biotech and pharmaceutical industry, we believe Sara's leadership and experience in drug development spanning more than 25 years will significantly help bolster Unicycive's future growth. "We are thrilled to welcome Dr. Kenkare-Mitra to our Board of Directors and know that her extensive drug development and corporate leadersh

    9/6/23 7:03:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Unicycive Therapeutics Appoints Douglas Jermasek As Executive Vice President, Corporate Strategy

    LOS ALTOS, Calif., Oct. 26, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the appointment of Douglas Jermasek as Executive Vice President, Corporate Strategy. In this role, Mr. Jermasek, a seasoned healthcare professional, will have responsibility for Unicycive's corporate and commercial strategy and business development activities. Doug has spent the majority of his career focused on drugs for treatment of kidney diseases"With a career spent in heal

    10/26/21 7:30:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UNCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 7:13:38 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 7:01:14 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 5:46:12 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care